1. Home
  2. HBIO vs COCP Comparison

HBIO vs COCP Comparison

Compare HBIO & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

N/A

Current Price

$8.13

Market Cap

26.5M

Sector

Industrials

ML Signal

N/A

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

N/A

Current Price

$1.14

Market Cap

21.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HBIO
COCP
Founded
1901
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
21.6M
IPO Year
2000
2011

Fundamental Metrics

Financial Performance
Metric
HBIO
COCP
Price
$8.13
$1.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.8K
★ 50.2K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.65
EPS
N/A
★ N/A
Revenue
★ $116,176,000.00
$12,712,091.00
Revenue This Year
$3.76
N/A
Revenue Next Year
$5.29
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.38
$0.76
52 Week High
$8.40
$2.03

Technical Indicators

Market Signals
Indicator
HBIO
COCP
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
HBIO
COCP

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: